Pharmacokinetic parameters for estimating blood drug concentration-time (C-t) profiles from dissolution results (info-link).

DRUG	Elimination Rate Equation (h^{-1})	Volume of Distribution (V_d) (L/kg)	Bioavailability (F) (%)	Added/Revised
Diltiazem[1]	$C_0e^{-0.217t}$	5.3	44	November 28, 2011
Carbamezepine[2]	$C_0e^{-0.019t}$	1.26	100	November 28, 2011
Primidone[3]	$C_0e^{-0.0693t}$	0.75	95	November 28, 2011
Acetaminophen[4]	$C_0e^{-0.2235t}$	1.025	75.5	November 28, 2011
Prednisone[5]	$C_0e^{-0.231t}$	0.70	90	November 28, 2011
Trimethoprim (TMX)[6]	$C_0e^{-0.0693t}$	1.6	95	January 27, 2012
Sulfamethoxazole (SMX)[6]	$C_0e^{-0.0693t}$	0.26	100	January 27, 2012
Valproic Acid[6,7]	$C_0e^{-0.0495t}$	0.131	100	February 21, 2012
Metoprolol Tartrate[1,8]	$C_0e^{-0.173t}$	5.6	38	March 17, 2012
Deoxycycline Hyclate[9]	$C_0e^{-0.0398t}$	0.81	95	April 15, 2012
Nifedipine[1,10]	$C_0e^{-0.4175t}$	2.26	45	February 18, 2013
Gliclazide[11]	$C_0e^{-0.0423t}$	0.481	97	March 25, 2013
Milnacipran[12]	$C_0e^{-0.0866t}$	5.71	85	December 1, 2013
Body weight of 70 kg may be used for calculations				

1. Gilman, A.G.; Goodman, L.S.; Rall, T.W.; Murad, F., Eds. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 7th ed. MacMillan Publishing Co.: New York, 1985.
2. Kovacevic, I; Parojcic, J; Homsek, I; Tubic-Grozdanis, M; and Langguth, P. Justification of Biowaiver for Carbamazepine, a Low Soluble High Permeable Compound, in Solid Dosage Forms Based on IVIVC and Gastrointestinal Simulation. *Molecular Pharmaceutics*. 2008, 6, 40–47|
3. http://www.drugs.com/ppa/primidone.html Accessed. October 19, 2011
4. Kalantzi L, Reppas C, Dressman JB, Amidon GL, Junginger HE, Midha KK, Shah VP, Stavchansky SA, Barends DM Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). *J Pharm Sci*. 2006 95(1):4-14.
5. Vogt M, Derendorf H, Krämer J, Junginger HE, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. Biowaiver monographs for immediate release solid oral dosage forms: prednisone. *J Pharm Sci*. 2007, 96(6):1480-9.
6. Thummel KE, Shen DD, Isoherranen N. Appendix II. Design and Optimization of Dosage Regimens: Pharmacokinetic Data. In: Brunton LL, Chabner BA, Knollmann BC, eds. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 12nd ed. New York: McGraw-Hill; 2011.

7. Perucca *et al*. ERUCCA, Pharmacokinetics of valproic acid in the elderly, *Br. J. clin. Pharmac.* 17 (1984) 665-669.
8. Terry white chemists metoprolol tablets. http://www.pbs.gov.au/meds%2Fpi%2Ftwpmetop10808.pdf. Accessed: Friday, March 2, 2012
9. http://www.drug-dissolution-testing.com/?p=1535
10. http://www.drug-dissolution-testing.com/blog/files/nifedPK.pdf
11. Delrat, P., Paraire, M., Jochemsen, R., 2002. Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. Biopharm Drug Dispos 23, 151–157.
12. Singhvi, G., Shah, A., Yadav, N., Saha, R.N., 2013. Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Drug Dev Ind Pharm.